Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics

Core Viewpoint - Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, but there are concerns about its investment potential compared to other stocks like Eli Lilly [1] Company Overview - Viking Therapeutics is engaged in the development of therapies targeting metabolic and endocrine disorders [1] - The company has been mentioned in the context of a bidding war between Novo Nordisk and Pfizer for Metsera, indicating its relevance in the competitive landscape of biopharmaceuticals [1] Market Commentary - Jim Cramer expressed a preference for Eli Lilly over Viking Therapeutics, suggesting that if he were to invest in Viking, it would be in Viking Cruises instead [1] - Cramer noted that Viking Therapeutics might have received a bid if it were expected, but he believes that the ongoing bidding war could lead to a potential acquisition of Viking by the losing party [1] Investment Perspective - While acknowledging the potential of VKTX, the article suggests that certain AI stocks may offer greater upside potential and lower downside risk compared to Viking Therapeutics [1]